Latest Breaking News On - ஜான் சேஜர்லைஸ் - Page 1 : comparemela.com
Xencor begins dosing in Phase I trial of autoimmune disease treatment 29 Apr 2021 (Last Updated April 29th, 2021 17:28)
Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases.
Share Article
The study will assess the safety, tolerability and pharmacokinetics of subcutaneously administered XmAb564 in healthy adult subjects. Credit: Edgar Y Pardo from Pixabay.
Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases.
XmAb564 is a monovalent IL-2-Fc fusion protein that can selectively stimulate and expand regulatory T cells (Tregs) for treating autoimmune diseases.
John-desjarlaisAllen-yangTechnology-development-groupDevelopment-groupஜான்-சேஜர்லைஸ்ஆலன்-யாங்தொழில்நுட்பம்-வளர்ச்சி-குழுவளர்ச்சி-குழு